晚期乳腺癌FAC方案动脉灌注结合静脉化疗的临床观察  

Clinic study on neoadjuvant transarterial infusion combined with intravenous chemotherapy with FAC regimen in intermediate and advanced breast cancer

作　　者：赵海波[1] 王明玉[1] 

机构地区：[1]山东省肿瘤防治研究院内一科

出　　处：《中华肿瘤防治杂志》2008年第10期780-782,共3页Chinese Journal of Cancer Prevention and Treatment

基　　金：山东省卫生厅资助项目(2003-138)

摘　　要：为了探讨FAC方案新辅助动脉灌注结合静脉化疗在中晚期乳腺癌中的应用价值,对36例ⅡB～ⅢB期的乳腺癌患者手术前采用FAC方案新辅助动脉灌注结合静脉化疗,同时比较同期37例FAC方案单纯静脉新辅助化疗患者的临床疗效和组织学疗效。结果:动脉灌注结合静脉化疗组临床有效率为80.6%,优于单纯静脉化疗患者组的54.1%,差异有统计学意义,χ2=5.016,P=0.025。动脉灌注结合静脉化疗组组织学有效率为91.7%,优于单纯静脉化疗组的67.6%。差异有统计学意义,χ2=6.491,P=0.011。初步研究结果提示,FAC方案新辅助动脉灌注结合静脉化疗是中晚期乳腺癌的有效方法,极具临床应用前景。The objective of this study was to investigate and evaluate the application of neoadjuvant transarterial infusion combined with intravenous chemotherapy with FAC regimen in intermediate and advanced breast cancer. Transarterial infusion combined with intravenous chemotherapy underwent on 36 patients with confirmed breast cancer in stage ⅡB-ⅢB, simple intravenous transarterial chemotherapy underwent on another 37 patients as the contrast, and both followed a FAC regimen. The clinical total effective rate of transarterial infusion combined with intravenous chemotherapy was 80.6%, while that of simple intravenous chemotherapy was 54.1%,which showed a significant difference, χ^2= 5. 016,P=0. 025. The histomorphologic total effective rate of transarterial infusion combined with intravenous chemotherapy was 91.7 %, while that of simple intravenous chemotherapy was 67.6 %, which also showed a significant difference, χ^2=6. 491, P= 0.011. Neoadjuvant transarterial infusion combined with intravenous chemotherapy with FAC regimen is effective in intermediate and advanced breast cancer, which implies a great clinical perspective.

关 键 词：乳腺肿瘤/药物疗法 灌注 局部 化学疗法 辅助 治疗结果 

分 类 号：R737.9[医药卫生—肿瘤]